PLx Pharma Winddown (PLx Pharma Winddown) Days Inventory : 220.66 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). PLx Pharma Winddown's Average Total Inventories for the three months ended in Sep. 2022 was $3.53 Mil. PLx Pharma Winddown's Cost of Goods Sold for the three months ended in Sep. 2022 was $1.46 Mil. Hence, PLx Pharma Winddown's Days Inventory for the three months ended in Sep. 2022 was 220.66.

The historical rank and industry rank for PLx Pharma Winddown's Days Inventory or its related term are showing as below:

PLXPQ's Days Inventory is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 157.54
* Ranked among companies with meaningful Days Inventory only.

PLx Pharma Winddown's Days Inventory increased from Sep. 2021 (40.25) to Sep. 2022 (220.66). It might indicate that PLx Pharma Winddown's sales slowed down.

Inventory Turnover measures how fast the company turns over its inventory within a year. PLx Pharma Winddown's Inventory Turnover for the three months ended in Sep. 2022 was 0.41.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. PLx Pharma Winddown's Inventory-to-Revenue for the three months ended in Sep. 2022 was 9.15.

PLx Pharma Winddown Days Inventory Historical Data

The historical data trend for PLx Pharma Winddown's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Winddown Days Inventory Chart

PLx Pharma Winddown Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Days Inventory

Get a 7-Day Free Trial

98.79

PLx Pharma Winddown Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Inventory	Get a 7-Day Free Trial															40.25	237.74	245.77	429.65	220.66

Competitive Comparison of PLx Pharma Winddown's Days Inventory

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma Winddown's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PLx Pharma Winddown's Days Inventory Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma Winddown's Days Inventory distribution charts can be found below:

* The bar in red indicates where PLx Pharma Winddown's Days Inventory falls into.

PLx Pharma Winddown Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PLx Pharma Winddown's Days Inventory for the fiscal year that ended in Dec. 2021 is calculated as

	Days Inventory (A: Dec. 2021 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2020 )	+	Total Inventories (A: Dec. 2021 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2021 )	*	Days in Period
=	( (0.143	+	2.458)	/	2 )	/	4.805	*	365
=	1.3005					/	4.805	*	365
=	98.79

PLx Pharma Winddown's Days Inventory for the quarter that ended in Sep. 2022 is calculated as:

	Days Inventory (Q: Sep. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2022 )	+	Total Inventories (Q: Sep. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
=	( (3.883	+	3.178)	/	2 )	/	1.46	*	365 / 4
=	3.5305					/	1.46	*	365 / 4
=	220.66

PLx Pharma Winddown (OTCPK:PLXPQ) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

PLx Pharma Winddown's Inventory Turnover for the three months ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	1.46	/	3.5305
	=	0.41

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PLx Pharma Winddown's Inventory to Revenue for the three months ended in Sep. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	3.5305	/	0.386
	=	9.15

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

PLx Pharma Winddown Days Inventory Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

Executives

Rita M O'connor	officer: Chief Financial Officer	4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano	director, officer: Chief Executive Officer	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino	director, officer: Executive Chairman	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden	director	1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh	director	C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc	10 percent owner	1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman	officer: Chief Operating Officer	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden	officer: Acting Chief Financial Officer	2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381